Dupixent Asthma denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Dupixent for Asthma as Experimental — and Why That Denial Is Likely Wrong

An "experimental or investigational" denial for dupilumab (Dupixent) in asthma is surprising, because dupilumab received FDA approval for use in certain patients with moderate-to-severe asthma. However, Aetna may apply this label if your specific presentation does not match the exact indication described in its clinical policy — for example, if the plan's policy requires a particular inflammatory phenotype or add-on therapy status that is not clearly documented in your submitted records.

### Why This Denial Is Appealable

FDA approval is the foundational rebuttal to an "experimental" denial. Insurers may still restrict coverage to specific patient subgroups within an approved indication, but they cannot classify an FDA-approved use as experimental without a defensible clinical basis. Under ACA §2719 external review and ERISA §503 full-and-fair review, an independent reviewer can assess whether Aetna's "experimental" classification is consistent with current medical evidence and the FDA-approved labeling. External reviewers frequently overturn experimental denials for FDA-approved drugs when the clinical record shows the patient meets the approved indication.

### Your Appeal Timeline

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Standard decision within 30–60 days; expedited within 72 hours.
• External review: After internal denial, you generally have approximately four months to request independent external review. For urgent cases, expedited external review can deliver a binding decision within 72 hours.

### Documentation to Gather

1. Diagnosis confirmation — pulmonary function testing, specialist evaluation notes, and chart documentation confirming the diagnosis of moderate-to-severe asthma. 2. Phenotype documentation — laboratory and clinical records establishing the inflammatory profile relevant to the FDA-approved indication (your prescriber and the FDA labeling will specify what markers are required). 3. Prior treatment history — documentation of add-on controller therapies tried, with dates and outcomes, consistent with the add-on maintenance indication in the FDA label. 4. Prescriber medical-necessity letter — your physician should cite the FDA-approved indication explicitly, explain how your clinical profile matches it, and reference the relevant professional society guideline organization (e.g., the applicable GINA or NAEPP guideline framework) without relying on specific numbers. 5. FDA prescribing information — attach the current FDA-approved labeling to your appeal as a primary-source exhibit showing that this use is not experimental.

### Criteria-Mapping Structure

Obtain Aetna's clinical policy for dupilumab in asthma and compare it to the FDA label:

| Requirement (Aetna policy or FDA label) | Your Chart Evidence | |---|---| | Confirmed moderate-to-severe asthma | [PFT results, specialist notes] | | Qualifying inflammatory phenotype | [Lab or clinical documentation] | | Add-on to standard controller therapy | [Current medication list with dates] |

If Aetna's policy is more restrictive than the FDA label, note that in your appeal and ask the external reviewer to assess whether the restriction is consistent with current medical evidence and practice guidelines.